The DOI matches its Crossref record; 105 of the 107 references it cites were found in a registry or an index.
Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation
Open accessAbstract
BACKGROUND: Benzodiazepines (BZDs) are among the most prescribed sedative hypnotics and among the most misused and abused medications by patients, in parallel with opioids. It is estimated that more than 100 million Benzodiazepine (BZD) prescriptions were written in the United States in 2009. While medically useful, BZDs are potentially dangerous. The co-occurring abuse of opioids and BZD, as well as increases in BZD abuse, tolerance, dependence, and short- and long-term side effects, have prompted a worldwide discussion about the challenging aspects of medically managing the discontinuation of BZDs. Abrupt cessation can cause death. This paper addresses the challenges of medications suggested for the management of BZD discontinuation, their efficacy, the risks of abuse and associated medical complications. The focus of this review is on the challenges of several medications suggested for the management of BZD discontinuation, their efficacy, the risks of abuse, and associated medical complications. METHODS: An electronic search was performed of Medline, Worldwide Science, Directory of Open Access Journals, Embase, Cochrane Library, Google Scholar, PubMed Central, and PubMed from 1990 to 2017. The review includes double-blind, placebo-controlled studies for the most part, open-label pilot studies, and animal studies, in addition to observational research. We expand the search to review articles, naturalistic studies, and to a lesser extent, letters to the editor/case reports. We exclude abstract and poster presentations, books, and book chapters. RESULTS: The efficacy of these medications is not robust. While some of these medicines are relatively safe to use, some of them have a narrow therapeutic index, with severe, life-threatening side effects. Randomized studies have been limited. There is a paucity of comparative research. The review has several limitations. The quality of the documents varies according to whether they are randomized studies, nonrandomized studies, naturalistic studies, pilot studies, letters to the editors, or case reports. CONCLUSIONS: The use of medications for the discontinuation of BZDs seems appropriate. It is a challenge that requires further investigation through randomized clinical trials to maximize efficacy and to minimize additional risks and side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benzodiazepines are also incredibly effective at rapidly aborting convulsant activity in those with epilepsy or other seizure disorders [5].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently, the number of individuals seeking treatment for complications related to BZD use dependence is rising [5].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings
Denis, C., Fatseas, M., Lavie, E., & Auriacombe, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005194.pub2 · Cited by 150
RetractedBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., Abenavoli, L., D'Angelo, C., Caputo, F., Zambon, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61814-5 · Cited by 685
Benzodiazepine pharmacology and central nervous system-mediated effects.
(2013) · Europe PMC (PubMed Central) · Cited by 650
Antiepileptic Drug Mechanisms of Action
Macdonald, R. L., & Kelly, K. M. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb05996.x · Cited by 591
Taylor, C. P., Angelotti, T., & Fauman, E. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.09.008 · Cited by 565
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013
Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016) · American Journal of Public Health · doi:10.2105/ajph.2016.303061 · Cited by 531
Clinical Pharmacokinetics of Diazepam
Mandelli, M., Tognoni, G., & Garattini, S. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803010-00005 · Cited by 496
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Guide to Clinical Preventive Services: Report of the U S Preventive Services Task Force
U.S. Preventive Services Task Force (1996) · Medical Entomology and Zoology · Cited by 446
Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines
Jones, C. M., & McAninch, J. K. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.03.040 · Cited by 376
Antispasticity drugs: Mechanisms of action
Davidoff, R. A. (1985) · Annals of Neurology · doi:10.1002/ana.410170202 · Cited by 340
CLONIDINE IN BENZODIAZEPINE WITHDRAWAL
KESHAVAN, M. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92810-7 · Cited by 302
Mechanism of Action of Trazodone:a Multifunctional Drug
Stahl, S. M. (2009) · CNS Spectrums · doi:10.1017/s1092852900024020 · Cited by 266
Management of benzodiazepine misuse and dependence
Brett, J., & Murnion, B. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.055 · Cited by 260
Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures
French, J. A., Kugler, A. R., Robbins, J. L., Knapp, L. E., & Garofalo, E. A. (2003) · Neurology · doi:10.1212/01.wnl.0000068024.20285.65 · Cited by 239
Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis
Steenen, S. A., van Wijk, A. J., van der Heijden, G. J., van Westrhenen, R., de Lange, J., & de Jongh, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115612236 · Cited by 237
The assessment and treatment of performance anxiety in musicians
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.598 · Cited by 235
Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies
Suman-Chauhan, N., Webdale, L., Hill, D. R., & Woodruff, G. N. (1993) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(93)90155-3 · Cited by 225
Effects of Clonidine on Anxiety Disorders
Hoehn-Saric, R. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780360094011 · Cited by 225
Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212
How theories evolved concerning the mechanism of action of barbiturates
Löscher, W., & Rogawski, M. A. (2012) · Epilepsia · doi:10.1111/epi.12025 · Cited by 207
Tricyclic antidepressant overdose. A review
Frommer, D. A. (1987) · JAMA · doi:10.1001/jama.257.4.521 · Cited by 196
Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain
Löscher, W., Hönack, D., & Taylor, C. P. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90249-s · Cited by 193
Hameg, A., Bayle, F., Nuss, P., Dupuis, P., Garay, R. P., & Dib, M. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01515-0 · Cited by 185
Jones, C. M., Paulozzi, L. J., & Mack, K. A. (2014) · PubMed Central · Cited by 182
Lemoine, P., Kermadi, I., Garcia-Acosta, S., Garay, R. P., & Dib, M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.08.015 · Cited by 180
Guide to clinical preventive services. Report of the US Preventive Services Task Force.
Tw, A. (1991) · PubMed · Cited by 174
Benzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Picazo, O., & Fernández‐Guasti, A. (1995) · Brain Research · doi:10.1016/0006-8993(95)00254-n · Cited by 155
Clonidine in the Central Nervous System
Isaac, L. (1980) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198000021-00002 · Cited by 142
Schweizer, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810290060012 · Cited by 138
Petitjean, S., Ladewig, D., Meier, C. R., Amrein, R., & Wiesbeck, G. A. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328105e0f2 · Cited by 132
Comai, S., Ochoa‐Sanchez, R., & Gobbi, G. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.01.008 · Cited by 129
Ochoa‐Sanchez, R., Comai, S., Lacoste, B., Bambico, F. R., Domínguez-López, S., Spadoni, G., Rivara, S., Bedini, A., Angeloni, D., FRASCHINI, F., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2676-11.2011 · Cited by 128
Cellular and Molecular Actions of Lamotrigine: Possible Mechanisms of Efficacy in Bipolar Disorder
Xie, X., & Hagan, R. M. (1998) · Neuropsychobiology · doi:10.1159/000026527 · Cited by 128
Facilitation of Benzodiazepine Discontinuation by Melatonin: A New Clinical Approach
Garfinkel, D., Zisapel, N., Wainstein, J., & Laudon, M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.20.2456 · Cited by 127
Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings
Denis, C., Fatseas, M., Lavie, E., & Auriacombe, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005194.pub3 · Cited by 123
Cardiac Complications and Delirium Associated With Valerian Root Withdrawal
Garges, H. P., Varia, I., & Doraiswamy, P. M. (1998) · JAMA · doi:10.1001/jama.280.18.1566-a · Cited by 116
Propranolol in Chronic Anxiety Disorders
Kathol, R. G. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780250047005 · Cited by 115
Clinical Features in Poisonings by Tricyclic Antidepressants with Special Reference to the ECG
Thorstrand, C. (1976) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1976.tb06745.x · Cited by 115
Antiepileptic Drug Mechanisms of Action
Macdonald, R. L., & Kelly, K. M. (1993) · Epilepsia · doi:10.1111/j.1528-1157.1993.tb05918.x · Cited by 115
(-)Pentobarbital Opens Ion Channels of Long Duration in Cultured Mouse Spinal Neurons
Mathers, D. A., & Barker, J. L. (1980) · Science · doi:10.1126/science.6248961 · Cited by 111
Tiagabine for the Treatment of Generalized Anxiety Disorder
Rosenthal, M. H. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1016 · Cited by 111
Rickels, K., DeMartinis, N., García-España, F., Greenblatt, D. J., Mandos, L. A., & Rynn, M. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1973 · Cited by 110
Otto, M. W., McHugh, R. K., Simon, N. M., Farach, F. J., Worthington, J. J., & Pollack, M. H. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.04.002 · Cited by 95
Pharmacology of benzodiazepine receptors: an update.
Sieghart, W. (1994) · PubMed · Cited by 92
Zitman, F. G., & Couvée, J. E. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.4.317 · Cited by 91
Lancaster, S. G., & Gonzalez, J. P. (1989) · Drugs · doi:10.2165/00003495-198937020-00003 · Cited by 84
Rickels, K., Schweizer, E. E., España, F. G., Case, G. W., DeMartinis, N. A., & Greenblatt, D. J. (1999) · Psychopharmacology · doi:10.1007/s002130050798 · Cited by 83
Gerra, G., Zaimovic, A., Giusti, F., Moi, G., & Brewer, C. (2002) · Addiction Biology · doi:10.1080/1355621021000005973 · Cited by 82
Diseases of the Nervous System
(1960) · Postgraduate Medical Journal · doi:10.1136/pgmj.36.415.348-a · Cited by 82
Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal?
Poyares, D. R., Guilleminault, C., Ohayon, M. M., & Tufik, S. B. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00305-0 · Cited by 77
Pharmacologic Strategies for Discontinuing Benzodiazepine Treatment
Rickels, K., DeMartinis, N. A., Rynn, M. A., & Mandos, L. A. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912002-00003 · Cited by 70
Pharmacological strategies for detoxification
Diaper, A., Law, F. D., & Melichar, J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12245 · Cited by 68
The effectiveness of anticonvulsants in psychiatric disorders
Grunze, H. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.1/hcrgrunze · Cited by 67
Cantopher, T., Olivieri, S., Cleave, N., & Edwards, J. G. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.156.3.406 · Cited by 67
Hadley, S. J., Mandel, F. S., & Schweizer, E. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111405360 · Cited by 66
Side effects of phenobarbital in epilepsy: a systematic review
Zhang, L., Zeng, L., & Li, Y. (2011) · Epileptic Disorders · doi:10.1684/epd.2011.0444 · Cited by 61
Treatment of phenobarbital overdose with activated charcoal.
Goldberg, M. J., & Berlinger, W. G. (1982) · PubMed · Cited by 57
Schweizer, E. E., CASE, W. G., España, F. G., Rickels, K., & Greenblatt, D. J. (1995) · Psychopharmacology · doi:10.1007/bf02246214 · Cited by 53
Treatment of Phenobarbital Overdose With Activated Charcoal
Goldberg, M. J. (1982) · JAMA · doi:10.1001/jama.1982.03320420050032 · Cited by 50
Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse
Cardinali, D. P., Golombek, D. A., Rosenstein, R. E., Brusco, L. I., & Vigo, D. E. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.016 · Cited by 49
Sites of action of sleep and wake drugs: insights from model organisms
Rihel, J., & Schier, A. F. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.04.010 · Cited by 48
Lancaster, S. G., & Gonzalez, J. P. (1989) · Drugs · doi:10.2165/00003495-198938010-00005 · Cited by 47
Endogenous Melatonin is Not Obligatory for the Regulation of the Rat Sleep-Wake Cycle
Fisher, S. P., & Sugden, D. (2010) · SLEEP · doi:10.1093/sleep/33.6.833 · Cited by 46
Kawasaki, S. S., Jacapraro, J. S., & Rastegar, D. A. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.12.011 · Cited by 46
A Controlled Trial of Dothiepin and Placebo in Treating Benzodiazepine Withdrawal Symptoms
Tyrer, P. J., Ferguson, B., Hallström, C., Michie, M. H., Tyrer, S. P., Cooper, S. J., Caplan, R., & Barczak, P. (1996) · The British Journal of Psychiatry · doi:10.1192/bjp.168.4.457 · Cited by 46
Large, C. H., Kalinichev, M., Lucas, A., Carignani, C., Bradford, A., Garbati, N., Sartori, I., Austin, N. E., Ruffo, A., Jones, D. N. C., et al. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.02.018 · Cited by 45
Goodman, W. K., Charney, D. S., Price, L. H., Woods, S. W., & Heninger, G. R. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.7.900 · Cited by 44
Nakao, M., Takeuchi, T., Nomura, K., Teramoto, T., & Yano, E. (2006) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2006.01565.x · Cited by 44
The role of lamotrigine in the management of bipolar disorder
Ng, F., Hallam, K. T., Lucas, N., & Berk, M. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a920 · Cited by 43
Wright, A., Diebold, J., Otal, J., Stoneman, C., Wong, J., Wallace, C., & Duffett, M. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0322-5 · Cited by 43
Petrovic, M., Pevernagie, D., Mariman, A., Van Maele, G., & Afschrift, M. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0387-4 · Cited by 42
A Controlled Trial of Ondansetron, a 5-HT3 Antagonist, in Benzodiazepine Discontinuation
Romach, M. K., Kaplan, H. L., Busto, U. E., Somer, G. R., & Sellers, E. M. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199804000-00004 · Cited by 42
Meibach, R. C., Dunner, D., Wilson, L. G., Ishiki, D., & Dager, S. R. (1987) · PubMed · Cited by 38
Bourin, M., Dailly, É., & Hascoët, M. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00023.x · Cited by 33
Alprazolam dependence prevented by substituting with the β-carboline abecarnil
Pinna, G., Galici, R., Schneider, H. H., Stephens, D., & Turski, L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2719 · Cited by 32
Lormetazepam addiction: data analysis from an Italian medical unit for addiction
Leone, R., Faccini, Paiusco, Quaglio, Casari, Albiero, Donati, & Lugoboni (2012) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s31745 · Cited by 31
Analysis of benzodiazepine withdrawal program managed by primary care nurses in Spain
López-Peig, C., Mundet, X., Casabella, B., García, J. L. D. V., Tintorer, D. L., & Diogène, E. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-684 · Cited by 30
Withdrawal from alprazolam dependency using clonazepam: clinical observations.
Patterson, J. F. (1990) · PubMed · Cited by 29
Does clonidine alter anxiety in humans?
Redmond, D. E. (1982) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(82)91245-7 · Cited by 28
Dealing with drug-seeking behaviour
James, J. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.022 · Cited by 28
Mariani, J. J., Malcolm, R. J., Mamczur, A. K., Choi, J. C., Brady, R., Nunes, E., & Levin, F. R. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2015.1125493 · Cited by 27
Use of carbamazepine in psychiatric disorders.
Birkhimer, L. J., Curtis, J. L., & Jann, M. W. (1985) · PubMed · Cited by 25
Topiramate in benzodiazepine withdrawal
Cheseaux, M., Monnat, M., & ZULLINO, D. F. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.497 · Cited by 24
Effect of valproic acid on anxiety-related behaviors in the rat
Lal, H., Shearman, G. T., Fielding, S., Dunn, R. W., Kruse, H., & Theurer, K. (1980) · Brain Research Bulletin · doi:10.1016/0361-9230(80)90093-3 · Cited by 22
Action of antiepileptic and anaesthetic drugs on Na- and Ca-spikes in mammalian non-myelinated axons
Elliott, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90226-v · Cited by 21
Valproate causes reduction of the excitatory amino acid aspartate in nerve terminals
Morland, C., Nordengen, K., & Gundersen, V. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.08.042 · Cited by 20
Employing mirtazapine to aid benzodiazepine withdrawal.
Chandrasekaran, P. K. (2008) · PubMed · Cited by 20
Effectiveness of flumazenil (RO 15-1788) in the treatment of benzodiazepine withdrawal
Gerra, G., Marcato, A., Caccavari, R., Affini, G. F., Fontanesi, B., Zaimovic, A., Avanzini, P., & Delsignore, R. (1993) · Current Therapeutic Research · doi:10.1016/s0011-393x(05)80679-4 · Cited by 19
Clonidine therapy in withdrawal from high-dose alprazolam treatment
Vinogradov, S., Reiss, A. L., & Csernansky, J. G. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.9.1188a · Cited by 18
Oxcarbazepine in rapid benzodiazepine detoxification
Croissant, B., Grosshans, M., Diehl, A., & Mann, K. (2008) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802149021 · Cited by 15
Trazodone in benzodiazepine dependence
Ansseau, M., & Roeck, J. D. (1992) · European Neuropsychopharmacology · doi:10.1016/0924-977x(92)90237-3 · Cited by 13
Hantouche, E. G., Guelfi, J., & Comet, D. (1998) · PubMed · Cited by 11
Natolino, F., Zanotti, A., Contarino, A., Lipartiti, M., & Giusti, P. (1996) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00170836 · Cited by 8
Baclofen in the short-term maintenance treatment of benzodiazepine dependence
Shukla, L., Kandasamy, A., Kesavan, M., & Benegal, V. (2014) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.145203 · Cited by 8
Significant lamotrigine overdose associated with acute pancreatitis
Nwogbe, B., Ferié, J., Smith, H., Gunawardena, I. D., & Dhatariya, K. (2009) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2009.080314 · Cited by 8
Long-Term Treatment and Relapse Prevention of Alcohol and Benzodiazepine Dependence with Lamotrigine
Pavlovic, Z. M. (2010) · Journal of Neuropsychiatry · doi:10.1176/jnp.2010.22.2.247.e25 · Cited by 8
For publication: Tiagabine in the discontinuation of long‐term benzodiazepine use
Oulis, P., Masdrakis, V. G., Karapoulios, E., Karakatsanis, N. A., Kouzoupis, A. V., & Papadimitriou, G. N. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2008.01890.x · Cited by 7
New aid to neurology: measurements with calibrated sedac.
Si, H., & Reiter, R. (1959) · PubMed · Cited by 4
Magro, L., Faccini, M., & Leone, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800634-4.00027-5 · Cited by 4
Clonidine in benzodiazepine withdrawal
Keshavan, M. S. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.4.530a · Cited by 3
Research works printed but not linked: 23
- Pal R, 2015, The ASAM essential of addiction medicine, 53
- SAMSHA, 2012, The DAWN report: highlights of the 2010 Drug Abuse Warning Network finding in drug-related emergency department visits
- Jones CM, 2014, MMWR Morb Mortal Wkly Rep, 63, 881
- Griffin CE, 2013, Ochsner J, 13, 214
- Sieghart W., 1994, J Psychiatry Neurosci, 19, 24
- Meibach RC, 1987, J Clin Psychiatry, 48, 355
- King TL, Brucker MC. Pharmacology for women’s health. 2nd ed. Sudbury: Jones & Bartlett Publishers, 2010, pp.372–373.
- Ng F, 2007, Neuropsychiatr Dis Treat, 3, 463
- Birkhimer LJ, 1985, Clin Pharm, 4, 425
- Kasson BJ., 1992, J Am Assoc Nurse Anesth, 60, 464
- Griffin CE, 2013, Ochsner J, 13, 214
- Comai S, 2013, Brain Res, 243, 231
- Faccini M, 2012, Risk Manag Healthc Policy, 5, 43
- Olsen RW, DeLorey TM. GABA receptor physiology and pharmacology. Basic neurochemistry: molecular, cellular and medical aspects. Lippincott-Raven, https://www.ncbi.nlm.nih.gov/books/NBK28090 (1999, accessed May 2017).
- Kumar AA, 2014, Int J Pharm Bio Sci, 5, 1
- 10.18773/austprescr.2015.055 · DOI · Paper page
- James J., 2016, Aust Prescr, 39, 96
- 10.1001/jama.1987.03390040137034 · doi:10.1001/jama.1987.03390040137034
- Patterson JF, 1990, J Clin Psychiatry, 51, 47
- Hantouche EG, 1998, Encephale, 24, 469
- Chandrasekaran PK., 2008, Singapore Med J, 49, 166
- 10.1007/BF02246214 · DOI
- 10.1007/s00228-001-0387-4 · DOI · Paper page
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“Currently, the number of individuals seeking treatment for complications related to BZD use dependence is rising [5].”
BackgroundBenzodiazepine Modulation of GABAA Receptors: A Mechanistic Perspective
Goldschen-Ohm, M. P. (2022) · Biomolecules · doi:10.3390/biom12121784 · Cited by 145
“Although largely successful, the prolonged use of BZDs can have undesirable side effects, including tolerance, dependence, withdrawal, and cognitive impairment [3,4].”
BackgroundKava as a Clinical Nutrient: Promises and Challenges
Bian, T., Corral, P., Wang, Y., Botello, J. F., Kingston, R., Daniels, T. F., Salloum, R. G., Johnston, E., Huo, Z., Lü, J., et al. (2020) · Nutrients · doi:10.3390/nu12103044 · Cited by 110
“At the same time, stress and anxiety are becoming more prevalent among the general population [174], while current pharmacologic treatments have only a modest clinical effect and carry a high burden of side effects [175,176].”
BackgroundGABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 94
“, equivalent of 100mg diazepam per day or more), hospitalization during the withdrawal period and pharmacological management of the symptoms is recommended (145, 146).”
BackgroundBenzodiazepines and Related Sedatives
Peng, L., Morford, K. L., & Levander, X. A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.012 · Cited by 85
Metadata
- Authors
- Fluyau, D., Revadigar, N., & Manobianco, B. E.
- Affiliations
- Emory University (US)
- Columbia University (US)
- Corresponding author
- Fluyau, Dimy
- ORCID
- Fluyau, Dimy
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-02-09
- Volume
- 8
- Issue
- 5
- Pages
- 147-168
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC5896864
- OpenAlex
- W2793118967
- Cited by
- 109
- References
- 107
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 8 · 2023: 15 · 2022: 19 · 2021: 18 · 2020: 14 · 2019: 8 · 2018: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepines, benzodiazepine withdrawal, benzodiazepine dependence, benzodiazepine discontinuation, pharmacological management, benzodiazepine misuse, drug tolerance, adverse effects, narrow therapeutic index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.